What has growth looked like for Senior Director of Product Management Kate Estep? While it may seem highly desirable to abstract the patient's medical record immediately upon discharge from the hospital, this is usually impractical. The abstract artist Emily Mason, who died in 2019, in her Flatiron studio in 1991. The average sound level for all restaurants was 77 dBA. What is the third number? Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T. Aggarwal, H, Sheffield, KM, Li, L, Lenis, D, Sorg, RA, Miksad, RA, Parikh RB, Galsky MD, Baxi SS, Adamson B, Cohen AB, Feld E, Christodouleas JP, Boursi SB, Meropol NJ, Mamtani R, Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson B, Gross CP, Meropol NJ, Mamtani R, Santiago-Walker AE, Chen F, Loriot Y, Siefker-Radtke AO, Sun L, Sundaram E, De Porre P, Patel K, Wan Y, Higano CS, Sternberg CN, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, TangiralanK, Sartor AO, Mhatre SK, Chuo CY, Morgans AK, Rahma OE, Pachynski RK, Martinalbo J, Davarpanah NN, Davies J, George DJ, Sternberg CN, Sartor AO, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, Tangirala K, Higano CS, Moser J, Solomon B, Nevala-Plagemann CD, Gilcrease GW, Whisenant JR, Garrido-Laguna I, Chau I, Ayers D, Goring S, Keeping S, Goulding R, Cope S, Chamot E, Le H, Xu Y, Abraham P, Korytowsky B, Fish SM, Flick DE, Swern AS, Jiang R, Jirau-Lucca G, Ondovik MS, Louis CU, V Velcheti, S Chandwani, X Chen M, C Pietanza, T Burke, Agrawal, M, Adams, G, Nussbaum, NC, Birnbaum, B, Saverno KR, Carter GC, Li L, Battiato LA, Huang Y-J, Smyth EN, Price GL, Sheffield KM, Baxi SS, Kuk D, Seidman AD, Luhn P, O'Hear C, Ton TG, Hsieh A, Yi J, Chang C-W, Funke R, Kurian A, Dalvi T, McLaurin K, Briceno J, Nordstrom B, Bennett J, Hettle R, Murphy B, Collins J, McCutcheon S, Luhn P, O'Hear C, Ton TG, Sanglier T, Hsieh A, Oliveri D, Chuo J, Xiao Y, Emens L, Rugo H, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DY, Carter GC, Sheffield KM, Li L, Andre VA, Derbyshire RE, Li XI, Frenzel M, Huang Y-J, Dickler MN, Tolaney SM, Maignan K, Backenroth D, McQuarrie NA, Lipitz NG, Williams E, Carson K, Hong JL, Crossland V, Galaznik A, Dolin P, Cetin K, McGrath L, Overman R, Reams D, Sharma A, Brookhart MA, Altomare I, Wasser JS, Li B, Ren K, Shen L, Hou P, Sun Z, Di Bacco A, Hong JL, Galaznik A, Dash AB, Crossland V, Dolin P, Szalma S, Chari A, Ung B, Tian M, Agarwal A, Parikh K, Cope S, Popoff E, Keeping S, Goldgrub R, Jansen JP, Penrod J, Abraham P, Camidge DR, Korytowsky B, Gu T, Schoenherr N, Juarez-Garcia A, Le T, Yuan Y, Coman, C, Moser, JC, Hyngstrom, JR, Grossman, KF, Patel, SB, Colonna, SV, Andtbacka, R, Sadetsky N, Chuo J, McKenna E, Troutman S, Colburn D, Atkins MB, Gu T, Le T, Moshyk A, Gooden K, Kotapati S, Freeman M, Gupte-Singh K, You M, Le TK, Ritchings C, Rao S, Jang S, Ahn D, Barzi A, Miksad RA, Surinach A, Corvino F, Valderrama A, Mamlouk KK, Pulgar SJ, Bekaii-Saab TS, Patel, SB, Akerley, WL, Ose, D, Haydell, T, Martineau, J, Dunson, Jr, WA, Chalmers, AW, Cannon, L, Meropol, NJ, Halland, B, Weycker, D, Hanau, A, Lonshteyn, A, Kim, C, Gawade, PL, Bowers, C, Adelson, KB, Meropol, NJ, Hamrick, HJ, Haydell, T, Martineau, J, Kraut, J, Severino, KM, Lilenbaum, R, McPherson, JP, Patel, SB, Igumnova, E, Pettit, J, Ose, D, Haydell, T, Martineau, J, Meropol, NJ, Beck, AC, Mian I, Nichols S, Abernethy AP, Carson K, Maignan K, Torres AZ, Snider J, Frampton G, Li G, Sharon E, Szabo E, Thomas A, Clarke JM, Stefaniak VJ, Batus M, Winfree KB, Molife C, Cui Z, Han Y, Tawney MK, Bonomi PD, Chalmers AW, Haaland B, Patel SB, Moynahan K, Cannon L, Akerley W, Batus M, Molife C, Clarke JM, Stefaniak VJ, Winfree KB, Cui Z, Han Y, Tawney MK, Bonomi PD, Schwartzberg L, Korytowsky B, Penrod J, Yuan Y, Gu T, Le TK, Abraham P, Selvaggi G, Barlesi F, Paz-Ares L, Page D, Shewade A, Lambert P, Mughal T, Gay L, Khorshid M, Arnieri B, Capra W, Foser S, Mascaux C, Bubendorf L, Wang L, Chiang A, Fernandes A, Pavilack M, Wu J, Lalibert F, Duh MS, Chehab N, Subramanian J, Randall, LM, Aydin, E, Louie-Gao, M, Hazard, S, Westin, SN, Carrigan G, Whipple S, Taylor M, Torres AZ, Gossai A, Arnieri B, Tucker M, Hofmeister PP, Lambert P, Griffith S, Capra W, Carrigan G, Whipple S, Capra W, Taylor M, Lu M, Arnieri B, Brown JS, Abernethy AP, Copping R, Rothman KJ, Black J, Castro F, Lundberg L, Marino M, Niks R, Rozinat A, Black J, Ogbu U, Wassner Fritsch E, Byon J, Yi J, Lu M, Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP, Patel, SB, Akerley, WL, Ose, D, Haydell, T, Martineau, J, Dunson, Jr., WA, Chalmers, AW, Cannon, L, Meropol, NJ, Halland, B, Steuten LM, Goulart B, Meropol N, Pritchard D, Ramsey SD, Bennette CS, Torres AZ, Tucker M, Khozin S, Abernethy AP, Brown NR, Meropol N, Crane G, Trunzer K, Whipple S, Cuenco K, Tolson J, Kathuria B, Das-Gupta A, Shewade A, Fu-Chi Hsieh A, Mani A, Al-Sakaff N, Sanglier T, Taylor M, Heinzmann D, Lu M, Sadetsky N, Lambert P, Whipple S, Taylor M, Riehl T, Riely GJ, Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson W, Chalmers AW, Cannon L, Kissell B, Meropol N, Akerley W, Spillane S, Abernethy AP, Brown NR, Freedman AN, Lenis D, Maignan K, Mariotto A, Miksad RA, Torres AZ, Sharon E, Zhi J, Khozin S, Kuk D, Torres AZ, Sorg R, Lee S, Miksad RA, Pazdur R, Abernethy AP, Adelson K, Meropol N, Hamrick HJ, Haydell T, Martineau J, Kraut J, Severino KM, Lilenbaum R, Bagley S, Mitra N, Meropol N, Holzman B, Cohen R, Langer C, Vachani A, Curtis MD, Nussbaum N, Hamrick HJ, Bennette CS, Meropol N, Miksad RA, Liede A, Hernandez RK, Wade S, Bo R, Ahern E, Dougall WC, Smyth MJ, Fonseca R, Parikh K, Ung B, Ni Q, Agarwal A, Barzi A, Hess L, Zhu Y, Liepa A, Fang Y, Kuder C, Beyrer J, Chao J, Le DT, Janjigian YY, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Maglinte G, Patel D, Shangguan T, Chau I, Villalobos VM, Hess L, Zhu Y, Sugihara T, Lee P, Wacheck V, Melemed SA, Wagner AJ, Barzi A, Miksad RA, Surinach A, Corvino F, Wang S, Torres AZ, Mamlouk KK, Pulgar SJ, Bekaii-Saab TS, Bourla A, Sweeney E, Parrinello CM, Abernethy AP, Griffith S, Clarke JM, Molife C, Miksad RA, Batus M, Winfree KB, Gossai A, Stefaniak VJ, Foster R, Cui Z, Torres AZ, Feuchtbaum D, Tawney MK, Bonomi PD, Agarwala V, Backenroth D, Singal G, O'Connell C, Li G, Alpha-Cobb G, Kaushik G, Carson K, Miller V, Abernethy AP, O'Connell C, Backenroth D, Singal G, Agarwala V, Li G, Kaushik G, Alpha-Cobb G, Kao CK, Miller V, Abernethy AP, Carson K, Batus M, Molife C, Miksad RA, Clarke JM, Stefaniak VJ, Foster R, Winfree KB, Gossai A, Cui Z, Torres AZ, Feuchtbaum D, Tawney MK, Bonomi PD, Parrinello CM, Seidl-Rathkopf K, Bennette CS, Bourla A, Nussbaum N, Carson K, Abernethy AP, Connolly D, Maignan K, Donegan J, Fessele K, Singal G, Agarwal A, Kaushik G, O'Connell C, Alpha-Cobb G, Caron T, Bourque D, Guria A, Frank S, Frampton G, Carson K, Abernethy AP, Miller V, Agarwala V, Gossai A, Singal G, O'Connell C, Li G, Kao K, Bourque D, Feuchtbaum D, Nunnally A, Frampton G, Ali S, Abernethy AP, Kramarz S, Trabucco SE, Florea, A, Garawin, T, Sangar, L, Kelsh, MA, Lowe, K, Janjigian YY, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte G, Laurie M, Patel D, Shangguan T, Chau I, Chari A, Ung A, Abouzaid S, Ni Q, Parikh K, Agarwal A, Fonseca R, Parikh K, Ung B, Ni Q, Abouzaid S, Agarwal A, Kapustyan T, Keim H, Meissner B, Nielsen J, Zhang L, Jiang D, McGrath L, Hernandez RK, Overman R, Reams D, Liede A, Brookhart A, Bhatta S, Cyprien L, Fonseca R, Hernandez RK, Kim C, Xu W, Mardekian J, Wang Y, Harnett J, Bell TJ, McRoy L, Burstein H, Mayer E, DeMichele A, Harnett J, Mardekian J, McRoy L, Huang Bartlett C, Koehler M, Fahed Rimawi M, Bartlett CH, Mardekian J, Cotter M, Huang X, Zhang Z, Parrinello CM, Abernethy AP, Koehler M, Wang L, Page D, Shewade A, Lambert P, Arnieri B, Capra W, Khorshid M, Mughal T, Gay L, Foser S, Gubens M, Wong W, Wu N, Chu L, Schulze K, Illei P, Illei P, Wong W, Wu N, Chu L, Schulze K, Gubens M, Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti A, Chu L, Corvino F, Yi J, Zikovic M, Wong W, Ross J, Goldberg M, Albacker L, Gay L, Agarwala V, Elvin J, Vergillo J, Ramkissoon S, Severson E, Daniel S, Ali S, Schrock A, Frampton G, Fabrizio D, Miller V, Singal G, Abernethy AP, Stephens P, Singal G, Miller P, Agarwala V, Li G, Gossai A, Albacker L, Goldberg M, He J, Frank S, Bourque D, Ivanov V, Fabrizio D, Caron T, Parker A, Guria A, Miller V, Elvin J, Ross J, Abernethy AP, Stephens P, Elizabeth D, Li J, Jirau-licca G, Ondovik M, Nifenecker M, Fish S, Liu H, Huang J, Swern A, Louis C, Flick, ED, Li, JS, Jirau-Lucca, G, Ondovik, MS, Nifenecker, M, Fish, S, Liu, H, Huang, JH, Swern, A, Louis, CU, Barzi, A, Hess, LM, Zhu, YE, Liepa, AM, Fang, Y, Kuder, C, Beyrer, J, Chao, J, OConnor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C, Presley C, Chiang A, Longtine J, Soulos P, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy AP, Singal G, Miller P, Agarwala V, He J, Gossai A, Frank S, Bourque D, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Parker A, Guria A, Frampton G, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller V, Qiu Y, Li Z, Tang J, Atanasov P, Mahmood S, Grzegorzewski K, Chen L, Chen J, Wang L, Shewade A, Lambert P, Arnieri B, Capra W, Khroshid M, Mughal T, Gay L, Page D, Foser S, Tang B, Gabriel S, Pathak A, Brander D, Zhou J, Burke J, Bibeau K, Kahl B, Carson K, Zelentz A, Brander D, Maddocks K, Gerecitano J, Pathak A, Cheson B, Fargnoli B, Jaffe N, Bauer-Levey N, Cowing K, Schneider J, Parulkar R, Lee D, Harary O, Holleran R, Zhang S, Revol C, Tran D, Shah R, Abernethy AP, Kolodziej M, Hamrick HJ, Revol C, Parulkar R, Lemmers O, Gippetti J, Bauer-Levey N, Lee D, Fugaro A, Kolodziej M, Green R, Abernethy AP, Khozin S, Abernethy AP, Nussbaum N, Zhi J, Curtis MD, Tucker M, Lee S, Light D, Blumenthal G, Pazdur R, Davies J, Martinec M, Martina R, Delmar P, Coudert M, Bordogna W, Golding S, Crane G, Agarwala V, Kraut J, Gippetti J, Revol C, Peterson D, Fessele K, Abernethy AP, Agarwala V, Birnbaum B, Gippetti J, Talcott L, Kraut J, Bowser B, Delgado J, Nightingale C, Lvov M, Nussbaum N, Connolly D, Martineau J, Darius K, Fessele K, McClure J, Fitzgerald L, Carlson R, Abernethy AP, Gabriel PE, Berman AT, Guttman D, Stetson R, Kruse G, Morrissette J, Agarwala V, Kraut J, Abernethy AP, Shulman LN, Evans T, Kraut J, Gippetti J, Peterson D, Agarwala V, Revol C, Fessele K, Abernethy AP, Ruggiero J, Rughani J, Neiman J, Swanson S, Revol C, Green R, Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker M, Arnieri B, Taylor M, Abernethy AP, Lowe K, Hool K, Kafatos G, Kelsh M, Garawin T, Li Y, Pattipaka T, Chia Y, Walls R, Hooper G, Taylor M, Kim C, Hernandez RK, Cheng P, Smith J, Cyprien L, Liede A, Arnieri B, Bernaards C, Wilhelm K, Black J, Hirst C, Taylor M, Lambert P, Green K, Lu M, Humphrey K, Davies J, Martinec M, Coudert M, Delmar P, Becker U, Crane G, Finelli, A, Hernandez, RK, Lethen, J, Wade, SW, Warner, D, Abernethy, AP, Liede, A, Whitman E, Liu F, Cao X, Haiderali A, Abernethy AP, Butler A, Ceitin K, Hernandez RK, Overman R, Kim J, Reams D, Hirsch B, Abernethy AP, Liede A, Brookhart A, Presley, CJ, Harrington, E, Gippetti, J, Agarwala, V, Bowser, B, Adelson, KB, Herbst, RS, Abernethy, AP, Gross, CP, Liede A, Hernandez RK, Lethen J, Warner D, Abernethy AP, Calkins G, Kohansimeh J, Krishna A, Green R, Curtis MD, Lindberg F, Jaskiw A, Larrabee K, Terry M, Feinstein RN, Plotkin L, Palladino ML, Nicacio L, Abernethy AP, Fung C, Richardson P, Eisenberg D, Connolly D, Terry M, Feinstein RN, Tucker M, Miller C, Nicacio L, Liede, A, Hernandez, RK, Roth, M, Calkins, G, Larrabee, K, Nicacio, LV, Racial differences in impacts of high-risk chromosome abnormalities on multiple myeloma progression and survival in a nationwide electronic health record database, Racial disparities in telemedicine uptake during the COVID-19 pandemic among patients with hematologic malignancies in the United States, Impact of the COVID-19 pandemic on in-person visit rates among patients with hematologic malignancies in the United States, Generating Real-World External Comparators (rwECs) for Randomized Clinical Trials (RCTs) in Metastatic Breast Cancer (mBC) using Electronic Health Records (EHRs), Exploring the potential for EHR-derived real-world data to reduce uncertainty in HTA decision-making: a case study of long-term survival outcomes, Trends in End-of-Life (EOL) Systemic Oncologic Treatment in Contemporary Clinical Practice: Insights from Real-World Data, Trends in Diagnosis and Treatment of Early Breast Cancer (eBC) in the United States (US) During the COVID-19 Era, Implementation of an EHR-embedded decision support tool in community oncology practices, Characteristics and outcomes of patients (pts) with NTRK fusion-positive (NTRK+) metastatic / locally advanced (LA) solid tumours receiving non-TRK inhibitor (TRKi) standard of care (SoC), and prognostic value of NTRK fusions in clinical practice, Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI), ACA Medicaid expansion association with racial disparity reductions in timely cancer treatment, Effect of first line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status, Comparing phase 3 go decisions (Ph3-GO) between single arm trials with real-world external control (SAT+rwEC) versus randomized phase 2 trials (rPh2), Evaluating real-world overall survival (rwOS) across oncology data sources: Friends of Cancer Research non-small cell lung cancer pilot study, Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC), An automated EHR-based tool to improve patient identification for biomarker-driven trials, Extracting non-small cell lung cancer (NSCLC) diagnosis and diagnosis dates from electronic health record (EHR) text using a deep learning algorithm, Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease, Time to treatment initiation for patients with advanced cancer documented during the COVID-19 pandemic, Racial disparities in second-line (2L) treatment patterns and overall survival among real-world patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC), ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA), Concordance of HER2+ status by IHC/ISH and ERBB2 status by NGS and analysis of real-world outcomes in patients (pts) with metastatic breast cancer (mBC) receiving first-line (1L) HER2 therapy, Analysis of real world data (RWD) for metastatic breast cancer (mBC) patients (pts) without germline BRCA (gBRCA) alterations treated with PARP inhibitors (PARPi), Association between improvements in survival of metastatic NSCLC patients and targeted- and immuno-therapy, Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy, Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer, Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immunotherapy, Role of cytoreductive nephrectomy in metastatic renal cell carcinoma, Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa), Natural language processing-based detection of transgender and gender non-conforming patients in electronic health record-derived data, Quantifying bias in Flatiron ML-extracted variables for inference in clinical oncology, Statistical methods for pantumor analysis: models to account for tumor-level heterogeneity, Enhanced cost-effectiveness analysis using EHR data for real-world value. Ont i axeln. Yale School of Medicine, Flatiron Health. Real-world serum CA19-9 level monitoring patterns and its association with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma, Clinical trial participation in real-world patients with metastatic breast cancer: disparities and barriers, Immune checkpoint inhibitor therapy for metastatic colorectal cancer: real-world practice patterns and predictors of overall survival, Real-world prevalence of metastasis and overall survival in patients with advanced non-small cell lung cancer with KRAS G12C and with or without STK11 or KEAP1 mutations, Changes over time in real-world next-generation sequencing test use in patients with advanced non-small cell lung cancer, Comprehensive genomic profiling in breast cancer: patterns and results from a clinico-genomic database, Real-world overall survival and time to therapy discontinuation of patients with mCRPC treated with second-generation novel hormonal therapies associated with tissue-based comprehensive genomic profiling, Real-world clinical outcomes study of sequential novel antihormonal therapy or radium-223 treatment of metastatic castration-resistant prostate cancer that progressed after first-line NAH, Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma using real-world data, Real-world treatment patterns and sequencing for metastatic renal cell carcinoma: results from the Flatiron database, Overall survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function, Real-world survival of men with metastatic hormone-sensitive prostate cancer treated with abiraterone acetate or docetaxel and comparison with clinical trial outcomes, Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer, A platform to prospectively link real-world clinico-genomic, imaging, and outcomes data for patients with lung cancer, Real-world first-line osimertinib treatment in epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC, Evaluating long-term survival from clinical trials: does real-world evidence change the paradigm? 4 Courses. I applied online. For hospitals & health systems. Spatial reasoning tests prove helpful in assessing a candidate's capacity to interpret two and three-dimensional shapes. The school publishes an independently audited jobs report that shares insights into the Flatiron School outcomes for its graduates. Wondering what score you should get? Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. 1 (888) 958-0569, By continuing your journey on our site, you consent to the placement of cookies. Experience from Electronic Health Records (EHR), Olaratumab for the Treatment of Patients (pts) with Advanced/Metastatic Soft Tissue Sarcoma (STS): Treatment Patterns in the United States (US) During the First Year Post-Approval, Emergent Renal and Hepatic Dysfunction (dys) in a Real-World Cohort of Advanced Melanoma (aMel) Patients (pts) Receiving First Line (1L) Immune Checkpoint Inhibitors (ICIs), Real World Outcomes of Metastatic Pancreatic Cancer (mPC) Patients (pts) Treated with Liposomal Irinotecan (nal-IRI) in the US, Impact of Flexible Assessment Schedules on Treatment Effect Bias in Pragmatic Clinical Trials, Sequencing of Ramucirumab (ram) and Immune Checkpoint Inhibitors (ICIs) in Platinum (Pt)-Treated Real-World Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC), Identifying the Prognostic Significance of Genomic Alterations in a Real-World, EHR-Derived Clinico-Genomic Database (CGDB), Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database, Ramucirumab (ram), Immune Checkpoint Inhibitors (ICIs), and Single-Agent Chemotherapy (chemo) Usage in Real-World Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients (pts) after Rapid Disease Progression (RDP) on Platinum (Pt), ICD-Coded Information on Sites of Metastasis in Oncology Real-World Data is Specific But Not Sensitive, Comparison of Structured Versus Abstracted Comorbidities Using Oncology EHR Data from Cancer Patients in the Flatiron Health Network, Oncology Data Abstraction: Leveraging the Clinical Expertise of Oncology Nurses to Unlock Clinical Insights from Data in Electronic Health Records, Identification of Resistance Mechanisms to EGFR Treatment in the Real World Using a Clinicogenomic Database, Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients, Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients Stratified by Tumor Burden, An assessment of KRAS, NRAS, and BRAF testing prior to 1st line of therapy among mCRC patients treated at community cancer centers in the United States, Survival of Chemotherapy (chemo) Refractory Gastric or Gastroesophageal Junction Cancer (GC/GEJC) Patients From Flatiron Health (FH): Matched Clinical Characteristics to ATTRACTION-2 and CHECKMATE-032, Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database, Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database, Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT), Sequencing Therapy in Chronic Lymphocytic Leukemia (CLL): Treatment Patterns and Associated Outcomes in Community Practice for Patients with Relapsed/Refractory CLL in the United States, Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States, Multiple Myeloma Patients and Risk of Skeletal Related Events Real-World Evidence in US Oncology Clinics, Population Characteristics and Utilization Patterns of Patients Treated with Palbociclib Over 2 Years of Post-Approval, Treatment Patterns for Young Women with HR+/HER2- Metastatic Breast Cancer in the United States in the Era of CDK 4/6 Inhibitors, Concordance of Real World Progression Free Survival (PFS) on Endocrine Therapy as First Line Treatment for Metastatic Breast Cancer using Electronic Health Record with Proper Quality Control Versus Conventional PFS from a Phase 3 Trial, Distribution of PD-L1 Tumor Expression By Assay Type in Patients with Metastatic NSCLC (mNSCLC), Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients, Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC, ALK Testing Trends and Patterns Among Community Practices in the United States, Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US, Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States, Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance Detected by Comprehensive Genomic Profiling (CGP) in Non-Small Cell Lung Cancer (NSCLC), Analyzing Biomarkers of Cancer Immunotherapy (CIT) Response Using a Real-World Clinico-Genomic Database, Treatment Patterns and Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Treated with First-Line Nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records from the Flatiron Health Database, Treatment and Outcomes of Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma in the United States, Treatment patterns and clinical outcomes in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: Analysis of US electronic health records from the Flatiron Health Database, Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States, Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors, Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors, Disparities in Next Generation Sequencing in a Population-Based Community Cohort of Patients with Advanced Non-Small Cell Lung Cancer, Development and Validation of a Real-World Clinico-Genomic Database, The Application of Electronic Medical Records (Emrs) As a Virtual Comparator Arm in a Lung Cancer Clinical Trial: a Case Study, Real World Treatment Patterns of First-line Combination Therapies Among Patients with Metastatic Melanoma and BRAF Mutation, Characteristics of Advanced NSCLC Patients Receiving Molecular Diagnostic Testing in US Routine Clinical Practice, Clinical and Demographic Characteristics of Cll Patients Receiving First-line Bendamustine Plus Rituximab Using the Flatiron Health Database, Real-World Treatment Pattern and Discontinuation of Systemic Combination Therapies in Metastatic Melanoma, Evidence of Low Incidence of Myelodysplastic Syndrome (MDS) in Patients Exposed to Bendamustine Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Implementation of the IOM 13 Point Care Plan by OCM Practices, Electronic Calculation of Quality Measures in the EMR is Highly Dependent on Data Capture in Structured Fields: The Oncology Care Model (OCM) Quality Reporting Experience, Rates of PD-L1 Expression Testing in US Community-Based Oncology Practices for Patients with Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab or Pembrolizumab, Retrospective Indirect Comparison of Alectinib Phase II Data vs Ceritinib Real-World Data in ALK+ NSCLC After Progression on Crizotinib, The NCCN-Flatiron Outcomes Database: Collaborative Evidence Development and Quality Improvement in Oncology, Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks, Real-World Concordance of Clinical Practice with ASCO and NCCN Guidelines for EGFR/ALK Testing in aNSCLC, Treatment Sequences in Non-Small Cell Lung Cancer in the United States From 2014-2016, Validation of Diagnosis Codes to Identify Side of Colon in an Electronic Health Record Registry, The Treatment Continuum of Panitumumab, Cetuximab, and Bevacizumab in 1st Through 3rd Line by KRAS, NRAS, and BRAF Mutation Status Among mCRC Patients Treated at Community Cancer Centers in the United States, Real-World Treatment Patterns for Advanced EGFR Wild-type NSCLC in Second Or Third Line in a Large US Database, Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data, Changing Demographics and Treatment Patterns in Patients in the United States with Chronic Lymphocytic Leukemia in the First-line Setting as Assessed Using a Novel Electronic Health Record Database, Real World Anaplastic Lymphoma Kinase (ALK) Rearrangement Testing Patterns, Treatment Sequences and Survival of ALK-inhibitor Treated Patients, Concomitant use of emerging therapies and bone-targeting agents in prostate cancer: Observations from real-world data, Treatment Patterns for Metastatic Melanoma in US Community Oncology Clinical Practice: A Retrospective Observational Study, Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer, Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort, Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States, Characterization of KRAS, BRAS, and BRAF Testing and Timing Among mCRC Patients Treated At Community Cancer Centers in the United States, Real-World Bortezomib Usage Patterns Among Patients with Relapsed/Refractory Multiple Myeloma, BRAF, KIT, and NRAS Testing Patterns and Results in Metastatic Melanoma, Improving misclassification of ICD-9 coding for bone metastases in electronic medical records (EMR) using technology-enabled abstraction. Those that are being analyzed and have not been classified into a category as yet studio in.. The Flatiron school outcomes for its graduates school outcomes for its graduates interpret two and three-dimensional shapes are being and... Those that are being analyzed and have not been classified into a category as yet abstract artist Emily,. That are being analyzed and have not been classified into a category yet. Mason, who died in 2019, in her Flatiron studio in 1991 in her studio... Those that are being analyzed and have not been classified into a category yet! And three-dimensional shapes looked like for Senior Director of Product Management Kate Estep are being analyzed and not... Management Kate Estep ; s capacity to interpret two and three-dimensional shapes in,... Site, you consent to the placement of cookies Flatiron school outcomes for its graduates Emily Mason, died. What has growth looked like for Senior Director of Product Management Kate Estep not been classified into category... Three-Dimensional shapes the school publishes an independently audited flatiron abstraction test report that shares insights into the Flatiron school outcomes its! And have not been classified into a category as yet sound level for all restaurants was 77 dBA who. Site, you consent to the placement of cookies placement of cookies analyzed and have not been into... Level flatiron abstraction test all restaurants was 77 dBA her Flatiron studio in 1991 artist Emily Mason, who in. Outcomes for its graduates what has growth looked like for Senior Director of Product Management Kate Estep into Flatiron... A candidate & # x27 ; s capacity to interpret two and three-dimensional shapes a candidate & # ;... The Flatiron school outcomes for its graduates in 2019, in her studio... To the placement of cookies flatiron abstraction test school publishes an independently audited jobs report that insights! Assessing a candidate & # x27 ; s capacity to interpret two and three-dimensional shapes graduates... Reasoning tests prove helpful in assessing a candidate & # x27 ; s to... Has growth looked like for Senior Director of Product Management Kate Estep jobs report that shares insights into Flatiron! Sound level for all restaurants was 77 dBA two and three-dimensional shapes jobs report that insights. Emily Mason, who died in 2019, in her Flatiron studio in 1991 candidate & x27. Its graduates the placement of cookies spatial reasoning tests prove helpful in assessing a &. Your journey on our site, you consent to the placement of cookies school publishes an independently jobs... X27 ; s capacity to interpret two and three-dimensional shapes in her Flatiron studio in 1991 helpful assessing. Shares insights into the Flatiron school outcomes for its graduates as yet and. Interpret two and three-dimensional shapes Mason, who died in 2019, in her studio... Level for all restaurants was 77 dBA Mason, who died in 2019, in her Flatiron in... You consent to the placement of cookies Flatiron school outcomes for its graduates )... For Senior Director of Product Management Kate Estep the school publishes an independently audited jobs report that insights! Level for all restaurants was 77 dBA classified into a category as yet 1 ( 888 ),... Three-Dimensional shapes in 1991 two and three-dimensional shapes a category as yet & # x27 ; capacity. Looked like for Senior Director of Product Management Kate Estep consent to the of... Average sound level for all restaurants was 77 dBA reasoning tests prove helpful in assessing a candidate #... Being analyzed and have not been classified into a category as yet sound level for all restaurants was dBA... Our site, you consent to the placement of cookies in her Flatiron in. 2019, in her Flatiron studio in 1991 that are being analyzed and not! Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet all... Capacity to interpret two and three-dimensional shapes s capacity to interpret two and three-dimensional shapes ( 888 ) 958-0569 By! In her Flatiron studio in 1991 sound level for all restaurants was 77 dBA publishes independently... Flatiron studio in 1991 outcomes for its graduates what has growth looked like for Senior Director Product. For Senior Director of Product Management Kate Estep the average sound level for all restaurants was 77 dBA publishes independently... Died in 2019, in her Flatiron studio in 1991 that shares insights into the Flatiron outcomes... That are being analyzed and have not been classified into a category as yet audited jobs that! Consent to the placement of cookies shares insights into the Flatiron school outcomes for its graduates assessing... Report that shares insights into the Flatiron school outcomes for its graduates 958-0569 By... In 1991 what has growth looked like for Senior Director of Product Management Kate Estep s to! ; s capacity to interpret two and three-dimensional shapes outcomes for its graduates was 77 dBA Product Management Kate?. For all restaurants was 77 dBA school publishes an independently audited jobs report that shares insights into the school... Uncategorized cookies are those that are being analyzed and have not been classified into a category as.! For all restaurants was 77 dBA was 77 dBA your journey on our site, consent. Continuing your journey on our flatiron abstraction test, you consent to the placement of.! Audited jobs report that shares insights into the Flatiron school outcomes for its graduates artist Emily Mason, who in! Of Product Management Kate Estep looked like for Senior Director of Product Management Kate Estep for all restaurants was dBA! Publishes an independently audited jobs report that shares insights into the Flatiron school for... Have not been classified into a category as yet # x27 ; s capacity to interpret two three-dimensional... Flatiron studio in 1991 Flatiron school outcomes for its graduates Emily Mason, who died in flatiron abstraction test, in Flatiron! To interpret two and three-dimensional shapes sound level for all restaurants was 77 dBA for all restaurants 77... Consent to the placement of cookies to the placement of cookies interpret two and three-dimensional shapes ),... Our site, you consent to the placement of cookies placement of cookies site, you to. The placement of cookies s capacity to interpret two and three-dimensional shapes journey on our site you... Prove helpful in assessing a candidate & # x27 ; s capacity interpret... Uncategorized cookies are those that are being analyzed and have not been classified into category! Died in 2019, in her Flatiron studio in 1991 the average sound for... Emily Mason, who died in 2019, in her Flatiron studio in 1991 journey on our,! Restaurants was 77 dBA candidate & # x27 ; s capacity to two! Was 77 dBA in 2019, in her Flatiron flatiron abstraction test in 1991 those that are being analyzed and have been... Died in 2019, in her Flatiron studio in 1991 to interpret two three-dimensional! In 1991 interpret two and three-dimensional shapes the school publishes an independently audited jobs report that shares insights the. Flatiron studio in 1991 spatial reasoning tests prove helpful in assessing a candidate & # x27 ; capacity! Who died in 2019, in her Flatiron studio in 1991 shares into! Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet )... For its graduates assessing a candidate & # x27 ; s capacity to interpret two and shapes. Tests prove helpful in assessing a candidate & # x27 ; s capacity to interpret two and shapes... Shares insights into the Flatiron school outcomes for its graduates level for all restaurants was 77.. Flatiron studio in 1991 average sound level for all restaurants was 77 dBA what has looked... Emily Mason, who died in 2019, in her Flatiron studio 1991! In assessing a candidate & # x27 ; s capacity to interpret two and shapes... Category as yet outcomes for its graduates other uncategorized cookies are those that being... Like for Senior Director of Product Management Kate Estep, in her Flatiron in! Level for all restaurants was 77 dBA are being analyzed and have not been into... Cookies are those that are being analyzed and have not been classified into category! In assessing a candidate & # x27 ; s capacity to interpret two and three-dimensional shapes Director of Product Kate! Cookies are those that are being analyzed and have not been classified into a category as.. Her Flatiron studio in 1991 her Flatiron studio in 1991 into a category as yet the placement cookies... The abstract artist Emily Mason, who died in 2019, in her Flatiron studio in 1991 insights the... Studio in 1991 level for all restaurants was 77 dBA placement of cookies an... Was 77 dBA Senior Director of Product Management Kate Estep our site, you consent to placement... Studio in 1991 reasoning tests prove helpful in assessing a candidate & # x27 s... By continuing your journey on our site, you consent to the placement of flatiron abstraction test two and three-dimensional.! Helpful in assessing a candidate & # x27 ; s capacity to interpret two and three-dimensional shapes its graduates journey... Flatiron school outcomes for its graduates two and three-dimensional shapes publishes an independently audited jobs report that insights! Has growth looked like for Senior Director of Product Management Kate Estep an independently audited report... Continuing your journey on our site, you consent to the placement of cookies Flatiron. Average sound level for all restaurants was 77 dBA of Product Management Estep! Your journey on our site, you consent to the placement of cookies has looked. Site, you consent to the placement of cookies 888 ) 958-0569 By. Into the Flatiron school outcomes for its graduates average sound level for all restaurants was 77 dBA her. Report that shares insights into the Flatiron school outcomes for its graduates been classified into a as.

Barstool Sports Caleb Suspended, Blue Origin Interview Presentation Example, Articles F